HEMGENIX - AN OVERVIEW

Amount of suitable patients: CDEC mentioned the uncertainty in the number of individuals with moderately serious to serious hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some individuals that are categorized as possessing mild or average sickness could possibly have a significa